berezko / iStockphoto.com
The Patent Trial and Appeal Board upheld Acorda Therapeutics’ patents covering the drug Ampyra (dalfampridine) in a case against Kyle Bass’s Coalition for Affordable Drugs in a decision handed down yesterday.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PTAB, Acorda, Ampyra, patent, Coalition for Affordable Drugs, Kyle Bass, USPTO, inter partes review